This dataset confirms that cooperating mutations in TP53-mutated malignancies are distinct from those in other subtypes of AML, with an absence in this cohort of mutations in common signaling genes like KIT and FLT3, and also WT1 [12,28] (Supplementary Table 3). This evidence concerns the gene TP53 and acute myeloid leukemia.